We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Patient and Clinician Characteristics Associated with Use of Telemedicine for Buprenorphine Induction Among Medicare Beneficiaries.
- Authors
Patel, Sadiq Y.; Ortiz, Esteban G.; Barsky, Benjamin A.; Huskamp, Haiden A.; Busch, Alisa B.; Mehrotra, Ateev
- Abstract
While existing evidence suggests that telemedicine may be a safe option for buprenorphine induction,[6] there is a need for more research comparing patient outcomes with telemedicine vs. in-person buprenorphine inductions. The 2008 Ryan Haight Act generally requires an in-person medical evaluation before the prescribing of medications such as buprenorphine for opioid use disorder (MOUD).[1],[2] Early in the COVID-19 pandemic (March 2020), the requirement was temporarily waived[3] and there was a sharp increase in MOUD inductions via telemedicine.[4] To inform debate about whether this waiver should be permanent, we identified characteristics of patients and clinicians associated with receiving a telemedicine (vs. in-person) induction during the pandemic.
- Subjects
PHYSICIANS' assistants; MEDICAID beneficiaries; MEDICARE beneficiaries; MEDICAL personnel; BUPRENORPHINE; OPIOID abuse
- Publication
JGIM: Journal of General Internal Medicine, 2022, Vol 37, Issue 14, p3758
- ISSN
0884-8734
- Publication type
Article
- DOI
10.1007/s11606-022-07633-y